Document Detail


Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer.
MedLine Citation:
PMID:  18054408     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate the progression-free rate (PFR) at 3 months (13+/-1 weeks), antitumor response, time-to-event efficacy endpoints, and toxicity profile of plitidepsin administered as a 3-h continuous i.v. infusion at a dose of 5mg/m(2), every 2 weeks, to patients with chemotherapy pretreated advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: This was a multicenter, non-randomized, exploratory, phase II study. Treatment lasted until disease progression, unacceptable toxicity, patient refusal or treatment delay for >2 weeks. PFR (primary efficacy endpoint) and objective response rate (secondary efficacy endpoint) were evaluated according to RECIST, while the toxic profile of plitidepsin was assessed using the NCI-CTC, version 2.0. RESULTS: A total of 21 patients with a median age of 61 years and with locally advanced or metastatic non-resectable NSCLC, who had previously received only one line of chemotherapy in an advanced setting, received a total of 54 cycles of treatment (median of two cycles per patient; range: 1-8). Antitumor activity was seen in 3 (1 PR, 2 SD) out of 17 evaluable patients according to RECIST. One patient was responder for the primary (PFR at 13+/-1 weeks) and secondary efficacy endpoint (stable disease according to RECIST). Other two patients were non-responders for the primary efficacy endpoint, but had stable disease (not confirmed at weeks 13+/-1 due to previous withdrawal due to adverse events). With a median follow-up of 12.3 months, the median time to progression (TTP) and the median overall survival (OS) were 1.2 months and 4.3 months, respectively. The incidence of plitidepsin-related toxicities was low and most of them were mild-to-moderate in severity. The most common side effects were anemia, and asymptomatic and non-cumulative increases of gamma-glutamyltransferase (GGT) and liver transaminase levels. CONCLUSION: This study shows that plitidepsin 3-h continuous i.v. infusion (5mg/m(2)) every 2 weeks, was feasible and well tolerated in patients with pretreated NSCLC. The lack of evidence of antitumor activity precludes further studies with this plitidepsin schedule in this tumor setting.
Authors:
Christian Peschel; Joerg T Hartmann; Alexander Schmittel; Carsten Bokemeyer; Folker Schneller; Ulrich Keilholz; Dieter Buchheidt; Susana Millan; Miguel Angel Izquierdo; Ralf-Dieter Hofheinz
Related Documents :
2184548 - Mitoxantrone (m) and vinblastine (v) in the treatment of advanced breast cancer.
22173238 - Alveolar soft part sarcoma 'revisited': clinicopathological review of 47 cases from a t...
20720418 - Prospective study of vinorelbine and capecitabine combination therapy in chinese patien...
20948438 - Adoptive transfer of ebv-specific t cells results in sustained clinical responses in pa...
19151788 - Clinical features and prognosis of de novo diffuse large b-cell lymphoma with t(14;18) ...
8204348 - Vp-16, ifosfamide and cisplatin (vip) for extensive small cell lung cancer.
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article; Multicenter Study     Date:  2007-12-03
Journal Detail:
Title:  Lung cancer (Amsterdam, Netherlands)     Volume:  60     ISSN:  0169-5002     ISO Abbreviation:  Lung Cancer     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-06-02     Completed Date:  2008-10-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8800805     Medline TA:  Lung Cancer     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  374-80     Citation Subset:  IM    
Affiliation:
Technische Universität, III. Medizinische Klinik, München, Germany. christian.peschel@lrz.tu-muenchen.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anemia / chemically induced
Animals
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*,  adverse effects,  blood
Carcinoma, Non-Small-Cell Lung / blood,  drug therapy*,  pathology*
Depsipeptides / administration & dosage*,  adverse effects
Disease Progression
Disease-Free Survival
Female
Humans
Infusions, Intravenous
Lung Neoplasms / drug therapy*,  pathology*
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Transaminases / blood
Urochordata*
gamma-Glutamyltransferase / blood
Chemical
Reg. No./Substance:
0/Depsipeptides; 0/aplidine; EC 2.3.2.2/gamma-Glutamyltransferase; EC 2.6.1.-/Transaminases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fibroblast growth factors and Hedgehogs: at the heart of the epicardial signaling center.
Next Document:  Competition between targeting signals in hybrid proteins provides information on their relative in v...